An Open-label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Trial Profile

An Open-label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Daratumumab (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Sep 2017 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
    • 07 Sep 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.
    • 07 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top